Cargando…

Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per d...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokolova, Larysa, Hoerr, Robert, Mishchenko, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099171/
https://www.ncbi.nlm.nih.gov/pubmed/25057270
http://dx.doi.org/10.1155/2014/682439
_version_ 1782326447850913792
author Sokolova, Larysa
Hoerr, Robert
Mishchenko, Tamara
author_facet Sokolova, Larysa
Hoerr, Robert
Mishchenko, Tamara
author_sort Sokolova, Larysa
collection PubMed
description A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per day) or betahistine (32 mg per day) for 12 weeks. An 11-point numeric analogue scale, the Vertigo Symptom Scale—short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures. Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment. There was no significant intergroup difference with regard to changes in any outcome measure. Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales. Clinical global impression was rated “very much improved” or “much improved” in 79% of patients treated with EGb 761 and in 70% receiving betahistine. With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients. In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated. This trial is registered with controlled-trials.com ISRCTN02262139.
format Online
Article
Text
id pubmed-4099171
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40991712014-07-23 Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine Sokolova, Larysa Hoerr, Robert Mishchenko, Tamara Int J Otolaryngol Clinical Study A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo. One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per day) or betahistine (32 mg per day) for 12 weeks. An 11-point numeric analogue scale, the Vertigo Symptom Scale—short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures. Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment. There was no significant intergroup difference with regard to changes in any outcome measure. Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales. Clinical global impression was rated “very much improved” or “much improved” in 79% of patients treated with EGb 761 and in 70% receiving betahistine. With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients. In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated. This trial is registered with controlled-trials.com ISRCTN02262139. Hindawi Publishing Corporation 2014 2014-06-25 /pmc/articles/PMC4099171/ /pubmed/25057270 http://dx.doi.org/10.1155/2014/682439 Text en Copyright © 2014 Larysa Sokolova et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Sokolova, Larysa
Hoerr, Robert
Mishchenko, Tamara
Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
title Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
title_full Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
title_fullStr Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
title_full_unstemmed Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
title_short Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
title_sort treatment of vertigo: a randomized, double-blind trial comparing efficacy and safety of ginkgo biloba extract egb 761 and betahistine
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099171/
https://www.ncbi.nlm.nih.gov/pubmed/25057270
http://dx.doi.org/10.1155/2014/682439
work_keys_str_mv AT sokolovalarysa treatmentofvertigoarandomizeddoubleblindtrialcomparingefficacyandsafetyofginkgobilobaextractegb761andbetahistine
AT hoerrrobert treatmentofvertigoarandomizeddoubleblindtrialcomparingefficacyandsafetyofginkgobilobaextractegb761andbetahistine
AT mishchenkotamara treatmentofvertigoarandomizeddoubleblindtrialcomparingefficacyandsafetyofginkgobilobaextractegb761andbetahistine